OmniAb — Third Quarter 2026 Earnings Summary

OmniAb reported third-quarter 2026 revenue of $4.0 million, driven by increased service and xPloration sales, resulting in a net loss of $15.7 million. For the nine months ended September 30, 2026, total revenue reached $31.8 million, a significant increase from the prior year, while the company raised its full-year 2026 revenue guidance to a range of $35 million to $39 million. The company expanded commercial access to its xPloration platform and introduced a new peptide discovery offering called OmniTides. Additionally, OmniAb highlighted key partner milestones, including positive Phase 2a results for Teva's TEV-408 and regulatory approval in China for Harbour BioMed's batoclimab.